公开(公告)号：WO2019115684A1

公开(公告)日：2019-06-20

申请号：PCT/EP2018/084738

申请日：2018-12-13

Applicant: SCIENCONS AS

Inventor： LARSEN, Roy Hartvig

IPC: A61K51/04 ,  A61P35/04 ,  A61P35/00 ,  A61K103/40 ,  A61K103/00

CPC classification number: C07F7/24 ,  A61K51/0402 ,  A61K51/0497 ,  A61P35/00 ,  A61P35/04 ,  C07B59/002 ,  C07B2200/05 ,  C07F3/003 ,  C07F9/94

Abstract: The present invention relates to complexes comprising a prostate- specific membrane antigen (PSMA) targeting compound linked to a radionuclide, such as 212 Pb or 227 Th, through a TCMC or DOTA chelating moiety. These compounds, and pharmaceutical compositions comprising them, can be used for medical applications. These applications include the treatment of prostate cancer, and the complexes allow for dual targeting of cancers.

公开(公告)号：WO2017220767A1

公开(公告)日：2017-12-28

申请号：PCT/EP2017/065508

申请日：2017-06-23

Applicant: SCIENCONS AS

Inventor： LARSEN, Roy Hartvig

IPC: A61K51/10

Abstract: The present invention relates to the generation of lead-212 for therapeutic use. Specifically, are methods related to the generation of lead-212 based radio labelled proteins, such as radioimmunoconjugates, embodiments of the present invention.

Abstract translation: 本发明涉及用于治疗用途的铅-212的产生。 具体而言，涉及与产生基于铅-212的放射性标记蛋白质如放射免疫缀合物，本发明的实施方案有关的方法。